News:   •  Restaurants   •  Library Catalog   •  Library Activities  •  History   •  Facebook / Twitter / RSS

Monrovia's Xencor Loses Less Money Than Anticipated - Stock Moves Up

Monrovia's biotech firm, Xencor, which is developing antibodies for autoimmune diseases and cancer, reported a second quarter loss of $16 million, or $0.30 per share, but its stock closed higher because the loss was less than anticipated.

- Brad Haugaard

No comments:

Post a Comment